


Methods in
Molecular Biology 1317

Springer Protocols

Wolfgang Walther
Ulrike Stein *Editors*



Gene Therapy of Solid Cancers

Methods and Protocols

 Humana Press

METHODS IN MOLECULAR BIOLOGY

Series Editor

John M. Walker

School of Life and Medical Sciences

University of Hertfordshire

Hatfield, Hertfordshire, AL10 9AB, UK

For further volumes:

<http://www.springer.com/series/7651>

Gene Therapy of Solid Cancers

Methods and Protocols

Edited by

Wolfgang Walther and Ulrike Stein

*Translational Oncology of Solid Tumors, Experimental and Clinical Research Center,
Charité University Medicine Berlin and Max-Delbrück-Center for Molecular Medicine,
Berlin, Germany*

 Humana Press

Editors

Wolfgang Walther
Translational Oncology of Solid Tumors,
Experimental and Clinical Research Center
Charité University Medicine Berlin and Max-
Delbrück-Center for Molecular Medicine
Berlin, Germany

Ulrike Stein
Translational Oncology of Solid Tumors,
Experimental and Clinical Research Center
Charité University Medicine Berlin and Max-
Delbrück-Center for Molecular Medicine
Berlin, Germany

ISSN 1064-3745 ISSN 1940-6029 (electronic)
Methods in Molecular Biology
ISBN 978-1-4939-2726-5 ISBN 978-1-4939-2727-2 (eBook)
DOI 10.1007/978-1-4939-2727-2

Library of Congress Control Number: 2015940999

Springer New York Heidelberg Dordrecht London
© Springer Science+Business Media New York 2015

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.

Printed on acid-free paper

Humana Press is a brand of Springer
Springer Science+Business Media LLC New York is part of Springer Science+Business Media (www.springer.com)

Preface

Gene therapy of cancer still represents the major field of research activities and clinical efforts in gene therapy. Therefore, generating informative and representative updates in this field is becoming increasingly important but also challenging. In this new edition the editors focus on coverage of gene therapies particularly aiming at treatment of solid tumors. Solid tumors are of great clinical importance, since they cover tumor entities, which are of highest incidence, such as colon, breast, lung, and prostate cancer. Therefore, solid tumors represent the primary target of cancer gene therapies.

This new edition is making the attempt to provide broad and representative insights into recent developments of experimental and clinical strategies for cancer gene therapy, knowing that it is quite ambitious, if not almost impossible to cover all of the important ones.

As it lies in the tradition of these *Methods in Molecular Biology* editions, the majority of chapters are designed to provide step-by-step protocols of particular gene therapeutic strategies in combination with helpful technical notes and brief but very informative introductions to the specific experimental or clinical approach. This is fueled by the strong belief that apart from describing what has been achieved the description of how this was done is sometimes helpful for those working in the field or those who are just about getting in touch with this exciting research area. These chapters are complemented by non-protocol contributions providing overviews in current developments of novel technologies and gene therapeutic approaches. Furthermore important issues in the context of clinical gene therapy, such as ethical aspects and guidelines of how clinical studies should be designed and performed, are included as valuable additions.

Berlin, Germany

*Wolfgang Walther
Ulrike Stein*

Contents

<i>Preface</i>	<i>v</i>
<i>Contributors</i>	<i>xi</i>
PART I IMMUNOGENE THERAPY	
1 Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy	3
<i>Georg Mahlknecht, Michael Sela, and Yosef Yarden</i>	
2 Gene Gun Her2/neu DNA Vaccination: Evaluation of Vaccine Efficacy in a Syngeneic Her2/neu Mouse Tumor Model.	17
<i>Tam Nguyen-Hoai, Antonio Pezzutto, and Jörg Westermann</i>	
3 MIDGE Technology for the Production of a Fourfold Gene-Modified, Allogenic Cell-Based Vaccine for Cancer Therapy	39
<i>Manuel Schmidt, Barbara Volz, Patrick Großmann, Kerstin Heinrich, and Burghardt Wittig</i>	
PART II SUICIDE GENE THERAPY	
4 Evaluation of Bystander Cell Killing Effects in Suicide Gene Therapy of Cancer: Engineered Thymidylate Kinase (TMPK)/AZT Enzyme-Prodrug Axis	55
<i>Takeya Sato, Anton Neschadim, Ryo Nakagawa, Teruyuki Yanagisawa, and Jeffrey A. Medin</i>	
5 Oncoleaking: Use of the Pore-Forming <i>Clostridium perfringens</i> Enterotoxin (CPE) for Suicide Gene Therapy	69
<i>Jessica Pable, Jutta Aumann, Dennis Kobelt, and Wolfgang Walther</i>	
6 iCaspase 9 Suicide Gene System	87
<i>Xiaoon Zhou, Antonio Di Stasi, and Malcolm K. Brenner</i>	
PART III GENE REPLACEMENT THERAPIES	
7 p53-Encoding pDNA Purification by Affinity Chromatography for Cancer Therapy	109
<i>Ángela Sousa, João A. Queiroz, and Fani Sousa</i>	
8 A qRT-PCR Method for Determining the Biodistribution Profile of a miR-34a Mimic	125
<i>Kevin Kelnar and Andreas G. Bader</i>	

PART IV GENE SUPPRESSION AND SIGNALING MODULATION THERAPY

- 9 Design and Selection of Antisense Oligonucleotides Targeting Transforming Growth Factor Beta (TGF- β) Isoform mRNAs for the Treatment of Solid Tumors 137
Frank Jaschinski, Hanna Korhonen, and Michel Janicot
- 10 RNA Interference for Antimetastatic Therapy 153
Mathias Dahlmann and Ulrike Stein
- 11 STAT3 Decoy ODN Therapy for Cancer. 167
Xiaoxia Sun and Jian Zhang

PART V ONCOLYTIC VIROTHERAPY AND BACTERIAL VECTORS FOR CANCER TREATMENT

- 12 Oncolytic Viral Therapy Using Reovirus 187
Chandini Thirukkumaran and Don G. Morris
- 13 Use of GLV-1h68 for Vaccinia Virotherapy and Monitoring 225
Alexa Frentzen, Ulrike Geissinger, Desislava Tsoneva, and Jochen Stritzker
- 14 Back to the Future: Are Tumor-Targeting Bacteria the Next-Generation Cancer Therapy? 239
Robert M. Hoffman

PART VI CLINICAL APPLICATION OF CANCER GENE THERAPY

- 15 Ethics of Cancer Gene Transfer Clinical Research 263
Jonathan Kimmelman
- 16 Planning an Academic Clinical Trial 287
Kim M. Champion and Gemma R. Jones
- 17 Production of Plasmid DNA as Pharmaceutical 315
Marco Schmeer and Martin Schleef
- 18 *Minicircle*: Next Generation DNA Vectors for Vaccination. 327
Martin Schleef, R. Schirmbeck, Michael Reiser, Marie Louise Michel, and Marco Schmeer

PART VII PROTOCOLS OF CLINICAL CANCER GENE THERAPY

- 19 A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma 343
Caroline J. Breibach, Anne Moon, James Burke, Tae-Ho Hwang, and David H. Kirn
- 20 Antiangiogenic Metargidin Peptide (AMEP) Gene Therapy in Disseminated Melanoma 359
Iben Spanggaard and Julie Gehl

21	Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors	365
	<i>Sophie Papa, May van Schalkwyk, and John Maher</i>	
	<i>Index</i>	383

Contributors

- JUTTA AUMANN • *Experimental and Clinical Research Center, Charité University Medicine Berlin, Berlin, Germany; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany*
- ANDREAS G. BADER • *Mirna Therapeutics, Austin, TX, USA*
- CAROLINE J. BREITBACH • *SillaJen Inc, Seoul, South Korea*
- MALCOLM K. BRENNER • *Center for Cell and Gene Therapy, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA; Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA*
- JAMES BURKE • *SillaJen Inc, Seoul, South Korea*
- KIM M. CHAMPION • *Joint Research Office, University College London, London, UK*
- MATHIAS DAHLMANN • *Translational Oncology of Solid Tumors, Experimental and Clinical Research Center, Charité University Medicine Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany*
- ALEXA FRENTZEN • *Genelux Corporation, San Diego, CA, USA*
- JULIE GEHL • *Department of Oncology, Center for Experimental Drug and Gene Electrotransfer, Copenhagen University Hospital Herlev, Herlev, Denmark*
- ULRIKE GEISSINGER • *Genelux Corporation, San Diego, CA, USA*
- PATRICK GROßMANN • *Mologen AG, Berlin, Germany*
- KERSTIN HEINRICH • *Mologen AG, Berlin, Germany*
- ROBERT M. HOFFMAN • *AntiCancer Inc., San Diego, CA, USA; Department of Surgery, University of California San Diego, San Diego, CA, USA*
- TEA-HO HWANG • *SillaJen Inc, Seoul, South Korea; Pusan National University and Medical Research Institute, Pusan National University, Busan, South Korea*
- MICHEL JANICOT • *Isarna Therapeutics, Preclinical Research and Development Department, Munich, Germany*
- FRANK JASCHINSKI • *Isarna Therapeutics, Preclinical Research and Development Department, Munich, Germany*
- GEMMA R. JONES • *Joint Research Office, University College London, London, UK*
- KEVIN KELNAR • *Mirna Therapeutics, Austin, TX, USA*
- JONATHAN KIMMELMAN • *Studies in Translation, Ethics and Medicine (STREAM), Biomedical Ethics Unit, McGill University, Montreal, QC, Canada*
- DAVID H. KIRN • *SillaJen Inc, Seoul, South Korea*
- DENNIS KOBELT • *Max-Delbrück-Center for Molecular Medicine, Berlin, Germany*
- HANNA KORHONEN • *Isarna Therapeutics, Preclinical Research and Development Department, Munich, Germany*
- JOHN MAHER • *Department of Research Oncology, King's College London, Guy's Hospital, London, UK; Department of Immunology, Barnet and Chase Farm NHS Trust, Hertfordshire, UK; Department of Clinical Immunology and Allergy, King's College Hospital, London, UK*

- GEORG MAHLKNECHT • *Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel; Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel*
- JEFFREY A. MEDIN • *Department of Medical Biophysics, University of Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada; University Health Network, Canadian Blood Services, Toronto, ON, Canada*
- MARIE-LOUISE MICHEL • *Department of Virology, Institut Pasteur, Paris cedex, France*
- ANNE MOON • *SillaJen Inc, Seoul, South Korea*
- DON G. MORRIS • *Southern Alberta Cancer Research Institute, University of Calgary, Calgary, AB, Canada; Tom Baker Cancer Centre, Calgary, AB, Canada; Department of Oncology and Medicine, University of Calgary, Calgary, AB, Canada*
- RYO NAKAGAWA • *Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan; Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan; University Health Network, Canadian Blood Services, Toronto, ON, Canada*
- ANTON NESCHADIM • *Center for Innovation, Canadian Blood Services, Toronto, ON, Canada*
- TAM NGUYEN-HOAI • *Laboratory for Molecular Immunotherapy, Charité University Medicine Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany*
- JESSICA PAHLE • *Experimental and Clinical Research Center, Charité University Medicine, Berlin, Germany; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany*
- SOPHIE PAPA • *Department of Research Oncology, King's College London, London, UK; Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK*
- ANTONIO PEZZUTTO • *Med. Klinik Hämatologie Onkologie/Tumorimmunologie, Charité University Medicine Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany*
- JOAO A. QUEIROZ • *CICS-UBI—Centro de Investigação em Ciências da Saúde, Universidade da Beira Interior, Covilhã, Portugal*
- MICHAEL REISER • *Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany; Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Charlestown, MA, USA*
- TAKEYA SATO • *Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan; University Health Network, Canadian Blood Services, Toronto, ON, Canada*
- MAY VAN SCHALKWYK • *Department of Research Oncology, King's College London, London, UK*
- R. SCHIRMBECK • *Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany*
- MARTIN SCHLEEF • *PlasmidFactory GmbH & Co. KG, Bielefeld, Germany*
- MARCO SCHMEER • *PlasmidFactory GmbH & Co. KG, Bielefeld, Germany*
- MANUEL SCHMIDT • *Mologen AG Berlin, Berlin, Germany*
- MICHAEL SELA • *Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel*
- ÂNGELA SOUSA • *CICS-UBI—Centro de Investigação em Ciências da Saúde, Universidade da Beira Interior, Covilhã, Portugal*

- FANI SOUSA • *CICS-UBI—Centro de Investigação em Ciências da Saúde, Universidade da Beira Interior, Covilhã, Portugal*
- IBEN SPANGGAARD • *Department of Oncology, Center for Experimental Drug and Gene Electrotransfer, Copenhagen University Hospital Herlev, Herlev, Denmark*
- ANTONIO DI STASI • *Bone Marrow Transplantation and Cell Therapy, University of Alabama at Birmingham, Birmingham, AL, USA*
- ULRIKE STEIN • *Translational Oncology of Solid Tumors, Experimental and Clinical Research Center, Charité University Medicine Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany*
- JOCHEN STRITZKER • *Genelux Corporation, San Diego, CA, USA; Department of Biochemistry, Biocenter University of Würzburg, Würzburg, Germany*
- XIAOXIA SUN • *Biology Department, Shandong Quality Inspection Center for Medical Devices, Jinan, China; Institute of Immunopharmacology & Immunotherapy, School of Pharmaceutical Sciences, Shandong University, Jinan, China*
- CHANDINI THIRUKKUMARAN • *Southern Alberta Cancer Research Institute, University of Calgary, Calgary, AB, Canada; Tom Baker Cancer Centre, Calgary, AB, Canada; Department of Oncology and Medicine, University of Calgary, Calgary, AB, Canada*
- DEISLAVA TSONEVA • *Department of Biochemistry, Biocenter, University of Würzburg, Würzburg, Germany*
- BARBARA VOLZ • *Mologen AG, Berlin, Germany*
- WOLFGANG WALTHER • *Translational Oncology of Solid Tumors, Experimental and Clinical Research Center, Charité University Medicine Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany*
- JÖRG WESTERMANN • *Med. Klinik Hämatologie Onkologie/Tumorimmunologie, Charité University Medicine Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany*
- BURGHARDT WITTIG • *Foundation Institute Molecular Biology and Bioinformatics, Freie Universität Berlin, Berlin, Germany*
- TERUYUKI YANAGISAWA • *Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan*
- YOSEF YARDEN • *Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel; Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel*
- JIAN ZHANG • *Institute of Immunopharmacology and Immunotherapy, School of Pharmaceutical Sciences, Shandong University, Jinan, China*
- XIAOOU ZHOU • *Center for Cell and Gene Therapy, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA*

